With the US in mid-regulatory review, stakeholders are keenly pushing for a safer and faster system, but there are different views on how these goals should be achieved. That was shown at a hearing of the US Senate's Special Committee on Aging1. The differing views also extend to the magnitude of the recall problem in the US
...
Regulatory Affairs Medtech
Assessing the size of the US recall issue
27 April 2011
Ashley Yeo
Not a subscriber ? Request a FREE Trial
Subscribe to Regulatory Affairs Medtech
RELATED CONTENT
NEWS
Regulatory Affairs Medtech News
- US FDA SOP seeks to convey new regulatory expectations to medtech firms faster
- US regulators unveil plan to transform FDA to global agency
- Stakeholders support exemption of in-house IVDs from EU directive, with conditions
- US FDA invites comments on introducing UDIs in electronic data healthcare systems
Other Informa News
ANALYSIS
Regulatory Affairs Medtech Analysis
EDITORIALS
Other Informa Editorials
FEATURES
Other Informa Features
COMMENT
Other Informa Comments
EVENTS
21September 2009
Minneapolis (MN), US
